4 recruiting, 1 completed, 1 not yet recruiting, 1 unknown. 5 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Recruiting 2, Completed 1, Not yet recruiting 1, Unknown 1 |
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Newave Pharmaceutical Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL) LP-118 - Philadelphia Positive Acute Lymphoblastic Leukemia | Phase 1 | Not yet recruiting | Wake Forest University Health Sciences | 26 | 2026-10-01 | 2026-06-05 |
| ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL Rocbrutinib, Pirtobrutinib - CLL / SLL, CLL (Chronic Lymphocytic Leukemia) | Phase 3 | Recruiting | Newave Pharmaceutical Inc | 306 | 2026-04-23 | 2026-08-11 |
| LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This LP-168, Obinutuzumab - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Zulfa Omer | 34 | 2025-06-01 | 2025-08-14 |
| Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. LP-118 - Non Hodgkin Lymphoma, Richter Transformation | Phase 1 | Recruiting | Newave Pharmaceutical Inc | 100 | 2022-05-08 | 2026-05-05 |
| Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. LP-168 - CLL/SLL, Waldenstrom Macroglobulinemia | Phase 1 | Recruiting | Newave Pharmaceutical Inc | 60 | 2021-07-19 | 2026-02-13 |
| Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML LP-108, LP-108 and azacitidine - AML/MDS, CMML | Phase 1 | Completed | Newave Pharmaceutical Inc | 32 | 2020-07-06 | 2026-01-23 |
| A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma LP-108 tablet - Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 74 | 2020-05-01 | 2023-05-01 |
Leukemia, Lymphocytic, Chronic, B-Cell (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Recurrence (3) · Leukemia, Myeloid, Acute (2) · Lymphoma, Non-Hodgkin (2) · Chromosome 17 deletion (1) · Hematologic Neoplasms (1) · Leukemia (1) · Leukemia, B-Cell (1) · Leukemia, Hairy Cell (1) · Leukemia, Prolymphocytic, T-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1)
Azacitidine (1) · obinutuzumab (1) · pirtobrutinib (1)
United States (6) · China (1) · Spain (1)
P30CA012197 (1)